The ESMO Deep Dive: First-Line Therapy for HRD-Negative Advanced Ovarian Cancer 2026 webinar, organized by the European Society for Medical Oncology (ESMO), will take place live on 2 September 2026 at 18:30 CEST.

The session will examine the reliability of current HRD testing, the role of PARP inhibitors in maintenance therapy, and the emerging potential of antibody–drug conjugates for patients with HRD-negative advanced ovarian cancer. Faculty include Isabelle L. Ray-Coquard, Charlie Gourley, Robert Louis Coleman, and Kathleen Nadine Moore. Registration is available exclusively to ESMO members, and live participants will receive a certificate of attendance and two ESMO-MORA Category 1 points.

Register Now.